Nerea Zabaleta

Dr. Nerea Zabaleta

Harvard Medical School, Boston, Massachusetts, USA
+1
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
DRDaniel Reichart
Daniel Reichart
GNGregory A. Newby
Gregory A. Newby
HWHiroko Wakimoto
Hiroko Wakimoto
MLMingyue Lun
Mingyue Lun
JGJoshua M. Gorham
Joshua M. Gorham
CSChristine Seidman
Christine Seidman
Dominant missense pathogenic variants in cardiac myosin heavy chain cause hypertrophic cardiomyopathy (HCM), a currently incurable disorder that increases risk for stroke, heart failure and sudden cardiac death. In this study, we assessed two different genetic therapies—an adenine base editor (ABE8e) and a potent Cas9 nuclease delivered by AAV9—to prevent disease in mice carrying the heterozygous HCM pathogenic variant myosin R403Q. One dose of dual-AAV9 vectors, each carrying one half of RNA-guided ABE8e, corrected the pathogenic variant in ≥70% of ventricular cardiomyocytes and maintained durable, normal cardiac structure and function. An additional dose provided more editing in the atria but also increased bystander editing. AAV9 delivery of RNA-guided Cas9 nuclease effectively inactivated the pathogenic allele, albeit with dose-dependent toxicities, necessitating a narrow therapeutic window to maintain health. These preclinical studies demonstrate considerable potential for single-dose genetic therapies to correct or silence pathogenic variants and prevent the development of HCM.

16 January 2023 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
PDF file
NZNerea Zabaleta
Nerea Zabaleta
CUCarmen Unzu
Carmen Unzu
NWNicholas D. Weber
Nicholas D. Weber
GGGloria Gonzalez-Aseguinolaza
Gloria Gonzalez-Aseguinolaza

5 January 2024 in EMBO Molecular Medicine
Verified
Journal Article
Open access
LTLaura Torella
Laura Torella
JKJulia Klermund
Julia Klermund
MBMartin Bilbao-Arribas
Martin Bilbao-Arribas
ITIbon Tamayo
Ibon Tamayo
GAGeoffroy Andrieux
Geoffroy Andrieux
GGGloria Gonzalez-Aseguinolaza
Gloria Gonzalez-Aseguinolaza
The therapeutic use of adeno-associated viral vector (AAV)-mediated gene disruption using CRISPR-Cas9 is limited by potential off-target modifications and the risk of uncontrolled integration of vector genomes into CRISPR-mediated double-strand breaks. To address these concerns, we explored the use of AAV-delivered paired Staphylococcus aureus nickases (D10ASaCas9) to target the Hao1 gene for the treatment of primary hyperoxaluria type 1 (PH1). Our study demonstrated effective Hao1 gene disruption, a significant decrease in glycolate oxidase expression, and a therapeutic effect in PH1 mice. The assessment of undesired genetic modifications through CIRCLE-seq and CAST-Seq analyses revealed neither off-target activity nor chromosomal translocations. Importantly, the use of paired-D10ASaCas9 resulted in a significant reduction in AAV integration at the target site compared to SaCas9 nuclease. In addition, our study highlights the limitations of current analytical tools in characterizing modifications introduced by paired D10ASaCas9, necessitating the development of a custom pipeline for more accurate characterization. These results describe a positive advance towards a safe and effective potential long-term treatment for PH1 patients.

2 November 2022 in Cell Reports Medicine
Verified
Journal Article
Open access
EZEric Zinn
Eric Zinn
CUCarmen Unzu
Carmen Unzu
PSPauline F. Schmit
Pauline F. Schmit
HTHeikki T. Turunen
Heikki T. Turunen
NZNerea Zabaleta
Nerea Zabaleta
LVLuk H. Vandenberghe
Luk H. Vandenberghe
Gene therapy is emerging as a modality in 21st-century medicine. Adeno-associated viral (AAV) gene transfer is a leading technology to achieve efficient and durable expression of a therapeutic transgene. However, the structural complexity of the capsid has constrained efforts to engineer the particle toward improved clinical safety and efficacy. Here, we generate a curated library of barcoded AAVs with mutations across a variety of functionally relevant motifs. We then screen this library in vitro and in vivo in mice and nonhuman primates, enabling a broad, multiparametric assessment of every vector within the library. Among the results, we note a single residue that modulates liver transduction across all interrogated models while preserving transduction in heart and skeletal muscles. Moreover, we find that this mutation can be grafted into AAV9 and leads to profound liver detargeting while retaining muscle transduction—a finding potentially relevant to preventing hepatoxicities seen in clinical studies.

10 May 2022 in Molecular Therapy
Verified
Journal Article
Open access
NZNerea Zabaleta
Nerea Zabaleta
UBUrja Bhatt
Urja Bhatt
CHCécile Hérate
Cécile Hérate
PMPauline Maisonnasse
Pauline Maisonnasse
JSJulio Sanmiguel
Julio Sanmiguel
LVLuk H. Vandenberghe
Luk H. Vandenberghe
The COVID-19 pandemic continues to have devastating consequences on health and economy, even after the approval of safe and effective vaccines. Waning immunity, the emergence of variants of concern, breakthrough infections, and lack of global vaccine access and acceptance perpetuate the epidemic. Here, we demonstrate that a single injection of an adenoassociated virus (AAV)-based COVID-19 vaccine elicits at least 17-month-long neutralizing antibody responses in non-human primates at levels that were previously shown to protect from viral challenge. To improve the scalability of this durable vaccine candidate, we further optimized the vector design for greater potency at a reduced dose in mice and non-human primates. Finally, we show that the platform can be rapidly adapted to other variants of concern to robustly maintain immunogenicity and protect from challenge. In summary, we demonstrate this class of AAV can provide durable immunogenicity, provide protection at dose that is low and scalable, and be adapted readily to novel emerging vaccine antigens thus may provide a potent tool in the ongoing fight against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).

13 November 2024 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
JDJiten Doshi
Jiten Doshi
ECEmma Couto
Emma Couto
JSJillian Staiti
Jillian Staiti
LVLuk H. Vandenberghe
Luk H. Vandenberghe
NZNerea Zabaleta
Nerea Zabaleta
The replication-defective adeno-associated virus (AAV) is extensively utilized as a research tool or vector for gene therapy. The production process of AAV remains intricate, expensive, and mechanistically underexplored. With the aim of enhancing AAV manufacturing efficiencies in mammalian cells, we revisited the questions and optimization surrounding the requirement of the various adenoviral helper genes in enabling AAV production. First, we refined the minimal set of adenoviral genes in HEK293 AAV production to E2A, L4-22 K /33 K, and VA RNA I. These findings challenge the previously accepted necessity of adenoviral E4orf6 in AAV production. In addition, we identified L4-22 K genes as crucial helpers for AAV production. Next, a revised minimal adenoviral helper plasmid comprising E2A, L4-22 K, and VA RNA I genes was designed and demonstrated to yield high titer and potent AAV preps in HEK293 transient transfection. Lastly, stable packaging cells harboring inducible E2A and L4-22 K genes were shown to maintain AAV production yields comparable to transient transfection over a culture period of ∼10 weeks. Combined, these findings further our understanding of adenoviral helper function in mammalian AAV production and provide novel plasmid and cell-line reagents with an improved safety profile for potential broad applicability in the research and gene therapy community.